First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.

"COMPETING INTERESTS Stefan Klein, Uwe Thuß and Christian Friedrich are employees of Bayer AG, Berlin, Germany. Sybille Baumann is an employee of CRS Clinical Research Services Berlin GmbH. Isabella Gashaw was previously employed by Bayer AG, Berlin, Germany and is now an employee of Boehringer Ingelheim, Ingelheim am Rhein, Germany. Xinying Chang was previously employed by Bayer AG, Berlin, Germany and is now an employee of Merck Serono, Beijing, China. Thomas Hummel, since 2018, has conducted research and received funding from: Sony, Stuttgart, Germany; Smell and Taste Lab, Geneva, Switzerland; Takasago, Paris, France; aspuraclip, Berlin, Germany; Baia Foods, Madrid, Spain; Frequency Therapeutics, Farmington, CT, USA."

"The authors would like to thank Antonia Kohnke (Bayer) for evaluation of pharmacokinetics. Medical writing services provided by Sarah Feeny of Adelphi Communications Ltd, Macclesfield, UK were funded by Bayer AG, Berlin, Germany in accordance with Good Publication Practice (GPP3) guidelines. This study was funded by Bayer AG. Bayer AG was responsible for study design, data collection, data analysis, data interpretation and study report writing. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit this paper for publication."